LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Endourological panorama and current state of training in endourology among European teaching hospitals.

    Ortega Polledo, Luis E / Mantica, Guglielmo / Carrión, Diego M / Khelif, Adrian / Subiela Henríquez, José D / González Padilla, Daniel A / Sanchís Bonet, Ángeles / Tamayo Ruiz, Juan C / García Rico, Eduardo / Alonso Gregorio, Sergio / Gómez Rivas, Juan / Esperto, Francesco / Scoffone, Cesare M / Cracco, Cecilia M / Checcucci, Enrico

    Minerva urology and nephrology

    2023  Volume 76, Issue 1, Page(s) 5–8

    Language English
    Publishing date 2023-12-13
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3062840-4
    ISSN 2724-6442
    ISSN (online) 2724-6442
    DOI 10.23736/S2724-6051.23.05646-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 16: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488].

    Sylvester, Richard J / Rodríguez, Oscar / Hernández, Virginia / Turturica, Diana / Bauerová, Lenka / Max Bruins, Harman / Bründl, Johannes / van der Kwast, Theo H / Brisuda, Antonin / Rubio-Briones, José / Seles, Maximilian / Hentschel, Anouk E / Kusuma, Venkata R M / Huebner, Nicolai / Cotte, Juliette / Mertens, Laura S / Volanis, Dimitrios / Cussenot, Olivier / Subiela Henríquez, Jose D /
    de la Peña, Enrique / Pisano, Francesca / Pešl, Michael / van der Heijden, Antoine G / Herdegen, Sonja / Zlotta, Alexandre R / Hacek, Jaromir / Calatrava, Ana / Mannweiler, Sebastian / Bosschieter, Judith / Ashabere, David / Haitel, Andrea / Côté, Jean-François / El Sheikh, Soha / Lunelli, Luca / Algaba, Ferran / Alemany, Isabel / Soria, Francesco / Runneboom, Willemien / Breyer, Johannes / Nieuwenhuijzen, Jakko A / Llorente, Carlos / Molinaro, Luca / Hulsbergen-van de Kaa, Christina A / Evert, Matthias / Kiemeney, Lambertus A L M / N'Dow, James / Plass, Karin / Čapoun, Otakar / Soukup, Viktor / Dominguez-Escrig, Jose L / Cohen, Daniel / Palou, Joan / Gontero, Paolo / Burger, Maximilian / Zigeuner, Richard / Mostafid, Amir Hugh / Shariat, Shahrokh F / Rouprêt, Morgan / Compérat, Eva M / Babjuk, Marko / van Rhijn, Bas W G

    European urology

    2023  Volume 83, Issue 5, Page(s) e140–e141

    Language English
    Publishing date 2023-02-24
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2023.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.

    Beijert, Irene J / Hentschel, Anouk E / Bründl, Johannes / Compérat, Eva M / Plass, Karin / Rodríguez, Oscar / Subiela Henríquez, Jose D / Hernández, Virginia / de la Peña, Enrique / Alemany, Isabel / Turturica, Diana / Pisano, Francesca / Soria, Francesco / Čapoun, Otakar / Bauerová, Lenka / Pešl, Michael / Bruins, H Maxim / Runneboom, Willemien / Herdegen, Sonja /
    Breyer, Johannes / Brisuda, Antonin / Calatrava, Ana / Rubio-Briones, José / Seles, Maximilian / Mannweiler, Sebastian / Bosschieter, Judith / Kusuma, Venkata R M / Ashabere, David / Huebner, Nicolai / Cotte, Juliette / Mertens, Laura S / Claps, Francesco / Masson-Lecomte, Alexandra / Liedberg, Fredrik / Cohen, Daniel / Lunelli, Luca / Cussenot, Olivier / El Sheikh, Soha / Volanis, Dimitrios / Côté, Jean-François / Rouprêt, Morgan / Haitel, Andrea / Shariat, Shahrokh F / Mostafid, A Hugh / Nieuwenhuijzen, Jakko A / Zigeuner, Richard / Dominguez-Escrig, Jose L / Hacek, Jaromir / Zlotta, Alexandre R / Burger, Maximilian / Evert, Matthias / Hulsbergen-van de Kaa, Christina A / van der Heijden, Antoine G / Kiemeney, Lambertus A L M / Soukup, Viktor / Molinaro, Luca / Gontero, Paolo / Llorente, Carlos / Algaba, Ferran / Palou, Joan / N'Dow, James / Ribal, Maria J / van der Kwast, Theo H / Babjuk, Marko / Sylvester, Richard J / van Rhijn, Bas W G

    European urology oncology

    2023  Volume 6, Issue 2, Page(s) 214–221

    Abstract: Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The ... ...

    Abstract Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive.
    Objective: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas.
    Design, setting, and participants: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018.
    Outcome measurements and statistical analysis: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution.
    Results and limitations: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p < 0.001) and longer than for T1 G3 (p = 0.002). Patients with Ta G3 NMIBC with concomitant carcinoma in situ (CIS) had worse prognosis and a similar time to progression as for patients with T1 G3 NMIBC with CIS (p = 0.5). Multivariable analyses for recurrence and progression showed similar results.
    Conclusions: The prognosis of Ta G3 tumors in terms of progression appears to be in between that of Ta G2 and T1 G3. However, patients with Ta G3 NMIBC with concomitant CIS have worse prognosis that is comparable to that of T1 G3 with CIS. Our results support the recent EAU NMIBC guideline changes for more refined risk stratification of Ta G3 tumors because many of these patients have better prognosis than previously thought.
    Patient summary: We used data from 17 centers in Europe and Canada to assess the prognosis for patients with stage Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC). Time to cancer progression for Ta G3 cancer differed from both Ta G2 and T1 G3 tumors. Our results support the recent change in the European Association of Urology guidelines for more refined risk stratification of Ta G3 NMIBC because many patients with this tumor have better prognosis than previously thought.
    MeSH term(s) Humans ; Neoplasm Staging ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/therapy ; Urinary Bladder Neoplasms/pathology ; Prognosis ; Carcinoma/diagnosis ; Carcinoma/pathology ; Urinary Bladder/pathology
    Language English
    Publishing date 2023-01-18
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2588-9311
    ISSN (online) 2588-9311
    DOI 10.1016/j.euo.2023.01.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

    Beijert, Irene J / Hentschel, Anouk E / Bründl, Johannes / Compérat, Eva M / Plass, Karin / Rodríguez, Oscar / Subiela Henríquez, Jose D / Hernández, Virginia / de la Peña, Enrique / Alemany, Isabel / Turturica, Diana / Pisano, Francesca / Soria, Francesco / Čapoun, Otakar / Bauerová, Lenka / Pešl, Michael / Bruins, H Maxim / Runneboom, Willemien / Herdegen, Sonja /
    Breyer, Johannes / Brisuda, Antonin / Calatrava, Ana / Rubio-Briones, José / Seles, Maximilian / Mannweiler, Sebastian / Bosschieter, Judith / Kusuma, Venkata R M / Ashabere, David / Huebner, Nicolai / Cotte, Juliette / Contieri, Roberto / Mertens, Laura S / Claps, Francesco / Masson-Lecomte, Alexandra / Liedberg, Fredrik / Cohen, Daniel / Lunelli, Luca / Cussenot, Olivier / El Sheikh, Soha / Volanis, Dimitrios / Côté, Jean-François / Rouprêt, Morgan / Haitel, Andrea / Shariat, Shahrokh F / Mostafid, A Hugh / Nieuwenhuijzen, Jakko A / Zigeuner, Richard / Dominguez-Escrig, Jose L / Hacek, Jaromir / Zlotta, Alexandre R / Burger, Maximilian / Evert, Matthias / Hulsbergen-van de Kaa, Christina A / van der Heijden, Antoine G / Kiemeney, Lambertus A L M / Soukup, Viktor / Molinaro, Luca / Gontero, Paolo / Llorente, Carlos / Algaba, Ferran / Palou, Joan / N'Dow, James / Ribal, Maria J / van der Kwast, Theo H / Babjuk, Marko / Sylvester, Richard J / van Rhijn, Bas W G

    International urology and nephrology

    2023  Volume 56, Issue 4, Page(s) 1323–1333

    Abstract: Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, ... ...

    Abstract Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial resection, restaging-TURB is required if the first resection was macroscopically complete but contained no detrusor muscle (DM) and second-TURB is advised for all completely resected T1-tumors with DM in the resection specimen. This study assessed the long-term outcomes after repeat-, second-, and restaging-TURB in T1-NMIBC patients.
    Methods: Individual patient data with tumor characteristics of 1660 primary T1-patients (muscle-invasion at re-TURB omitted) diagnosed from 1990 to 2018 in 17 hospitals were analyzed. Time to recurrence, progression, death due to bladder cancer (BC), and all causes (OS) were visualized with cumulative incidence functions and analyzed by log-rank tests and multivariable Cox-regression models stratified by institution.
    Results: Median follow-up was 45.3 (IQR 22.7-81.1) months. There were no differences in time to recurrence, progression, or OS between patients undergoing restaging (135 patients), second (644 patients), or repeat-TURB (84 patients), nor between patients who did or who did not undergo second or restaging-TURB. However, patients who underwent repeat-TURB had a shorter time to BC death compared to those who had second- or restaging-TURB (multivariable HR 3.58, P = 0.004).
    Conclusion: Prognosis did not significantly differ between patients who underwent restaging- or second-TURB. However, a worse prognosis in terms of death due to bladder cancer was found in patients who underwent repeat-TURB compared to second-TURB and restaging-TURB, highlighting the importance of separately evaluating different indications for re-TURB.
    MeSH term(s) Humans ; Non-Muscle Invasive Bladder Neoplasms ; Urinary Bladder Neoplasms/surgery ; Urinary Bladder Neoplasms/pathology ; Prognosis ; Urologic Surgical Procedures ; Urinary Bladder/surgery ; Urinary Bladder/pathology ; Cystectomy ; Neoplasm Staging
    Language English
    Publishing date 2023-11-19
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 204048-7
    ISSN 1573-2584 ; 0301-1623 ; 0042-1162
    ISSN (online) 1573-2584
    ISSN 0301-1623 ; 0042-1162
    DOI 10.1007/s11255-023-03867-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 733: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum.

    Beijert, Irene J / Hentschel, Anouk E / Bründl, Johannes / Compérat, Eva M / Plass, Karin / Rodríguez, Oscar / Subiela Henríquez, Jose D / Hernández, Virginia / de la Peña, Enrique / Alemany, Isabel / Turturica, Diana / Pisano, Francesca / Soria, Francesco / Čapoun, Otakar / Bauerová, Lenka / Pešl, Michael / Maxim Bruins, H / Runneboom, Willemien / Herdegen, Sonja /
    Breyer, Johannes / Brisuda, Antonin / Calatrava, Ana / Rubio-Briones, José / Seles, Maximilian / Mannweiler, Sebastian / Bosschieter, Judith / Kusuma, Venkata R M / Ashabere, David / Huebner, Nicolai / Cotte, Juliette / Mertens, Laura S / Masson-Lecomte, Alexandra / Liedberg, Fredrik / Cohen, Daniel / Lunelli, Luca / Cussenot, Olivier / El Sheikh, Soha / Volanis, Dimitrios / Côté, Jean-François / Rouprêt, Morgan / Haitel, Andrea / Shariat, Shahrokh F / Mostafid, A Hugh / Nieuwenhuijzen, Jakko A / Zigeuner, Richard / Dominguez-Escrig, Jose L / Hacek, Jaromir / Zlotta, Alexandre R / Burger, Maximilian / Evert, Matthias / Hulsbergen-van de Kaa, Christina A / van der Heijden, Antoine G / A L M Kiemeney, Lambertus / Soukup, Viktor / Molinaro, Luca / Gontero, Paolo / Llorente, Carlos / Algaba, Ferran / Palou, Joan / N'Dow, James / Ribal, Maria J / van der Kwast, Theo H / Babjuk, Marko / Sylvester, Richard J / van Rhijn, Bas W G

    European urology focus

    2022  Volume 8, Issue 6, Page(s) 1627–1634

    Abstract: Background: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports have consistently found a prevalence of 2-6% G1 in ... ...

    Abstract Background: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports have consistently found a prevalence of 2-6% G1 in their T1 series. However, it remains unclear if T1G1 carcinomas have added value as a separate category to predict prognosis within the non-muscle-invasive bladder cancer (NMIBC) spectrum.
    Objective: To evaluate the prognostic value of T1G1 carcinomas compared to TaG1 and T1G2 carcinomas within the NMIBC spectrum.
    Design, setting, and participants: Individual patient data for 5170 primary Ta and T1 bladder tumors from 17 hospitals in Europe and Canada were analyzed. Transurethral resection (TUR) was performed between 1990 and 2018.
    Outcome measurements and statistical analysis: Time to recurrence and progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox regression models stratified by institution.
    Results and limitations: T1G1 represented 1.9% (99/5170) of all carcinomas and 5.3% (99/1859) of T1 carcinomas. According to primary TUR dates, the proportion of T1G1 varied between 0.9% and 3.5% per year, with similar percentages in the early and later calendar years. We found no difference in time to recurrence between T1G1 and TaG1 (p = 0.91) or between T1G1 and T1G2 (p = 0.30). Time to progression significantly differed between TaG1 and T1G1 (p < 0.001) but not between T1G1 and T1G2 (p = 0.30). Multivariable analyses for recurrence and progression showed similar results.
    Conclusions: The relative prevalence of T1G1 diagnosis was low and remained constant over the past three decades. Time to recurrence of T1G1 NMIBC was comparable to that for other stage/grade NMIBC combinations. Time to progression of T1G1 NMIBC was comparable to that for T1G2 but not for TaG1, suggesting that treatment and surveillance of T1G1 carcinomas should be more like the approaches for T1G2 NMIBC in accordance with the intermediate and/or high risk categories of the European Association of Urology NMIBC guidelines.
    Patient summary: Although rare, stage T1 grade 1 (T1G1) bladder cancer is still diagnosed in daily clinical practice. Using individual patient data from 17 centers in Europe and Canada, we found that time to progression of T1G1 cancer was comparable to that for T1G2 but not TaG1 cancer. Therefore, our results suggest that primary T1G1 bladder cancers should be managed with more aggressive treatment and more frequent follow-up than for low-risk bladder cancer.
    MeSH term(s) Humans ; Non-Muscle Invasive Bladder Neoplasms ; Europe
    Language English
    Publishing date 2022-05-14
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2405-4569
    ISSN (online) 2405-4569
    DOI 10.1016/j.euf.2022.04.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.

    Sylvester, Richard J / Rodríguez, Oscar / Hernández, Virginia / Turturica, Diana / Bauerová, Lenka / Bruins, Harman Max / Bründl, Johannes / van der Kwast, Theo H / Brisuda, Antonin / Rubio-Briones, José / Seles, Maximilian / Hentschel, Anouk E / Kusuma, Venkata R M / Huebner, Nicolai / Cotte, Juliette / Mertens, Laura S / Volanis, Dimitrios / Cussenot, Olivier / Subiela Henríquez, Jose D /
    de la Peña, Enrique / Pisano, Francesca / Pešl, Michael / van der Heijden, Antoine G / Herdegen, Sonja / Zlotta, Alexandre R / Hacek, Jaromir / Calatrava, Ana / Mannweiler, Sebastian / Bosschieter, Judith / Ashabere, David / Haitel, Andrea / Côté, Jean-François / El Sheikh, Soha / Lunelli, Luca / Algaba, Ferran / Alemany, Isabel / Soria, Francesco / Runneboom, Willemien / Breyer, Johannes / Nieuwenhuijzen, Jakko A / Llorente, Carlos / Molinaro, Luca / Hulsbergen-van de Kaa, Christina A / Evert, Matthias / Kiemeney, Lambertus A L M / N'Dow, James / Plass, Karin / Čapoun, Otakar / Soukup, Viktor / Dominguez-Escrig, Jose L / Cohen, Daniel / Palou, Joan / Gontero, Paolo / Burger, Maximilian / Zigeuner, Richard / Mostafid, Amir Hugh / Shariat, Shahrokh F / Rouprêt, Morgan / Compérat, Eva M / Babjuk, Marko / van Rhijn, Bas W G

    European urology

    2021  Volume 79, Issue 4, Page(s) 480–488

    Abstract: Background: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do ... ...

    Abstract Background: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s.
    Objective: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression.
    Design, setting, and participants: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel.
    Intervention: Patients underwent TURBT followed by intravesical instillations at the physician's discretion.
    Outcome measurements and statistical analysis: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves.
    Results and limitations: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review.
    Conclusions: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary.
    Patient summary: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule.
    MeSH term(s) Humans ; Neoplasm Invasiveness ; Prognosis ; Retrospective Studies ; Urinary Bladder Neoplasms/therapy ; Urology ; World Health Organization
    Language English
    Publishing date 2021-01-06
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2020.12.033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top